Isotonic designs for phase I trials
Leung, D. H. Y. & Wang, Y-G. (2001) Isotonic designs for phase I trials. Controlled Clinical Trials, 22(2), pp. 126-138.
The purpose of a phase I trial in cancer is to determine the level (dose) of the treatment under study that has an acceptable level of adverse effects. Although substantial progress has recently been made in this area using parametric approaches, the method that is widely used is based on treating small cohorts of patients at escalating doses until the frequency of toxicities seen at a dose exceeds a predefined tolerable toxicity rate. This method is popular because of its simplicity and freedom from parametric assumptions. In this payer, we consider cases in which it is undesirable to assume a parametric dose-toxicity relationship. We propose a simple model-free approach by modifying the method that is in common use. The approach assumes toxicity is nondecreasing with dose and fits an isotonic regression to accumulated data. At any point in a trial, the dose given is that with estimated toxicity deemed closest to the maximum tolerable toxicity. Simulations indicate that this approach performs substantially better than the commonly used method and it compares favorably with other phase I designs.
Impact and interest:
Citation counts are sourced monthly from and citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Additional Information:||ISI Document Delivery No.: 421TE
Times Cited: 33
Cited Reference Count: 15
Leung, DHY Wang, YG
Elsevier science inc
|Keywords:||continual reassessment method, dose escalation, isotonic regression, maximum tolerated dose, phase I trials, up-and-down method, continual reassessment method, clinical-trials, dose-escalation, cancer, improvements|
|Divisions:||Current > QUT Faculties and Divisions > Science & Engineering Faculty|
|Copyright Owner:||Copyright Elsevier Science Inc. 2001|
|Deposited On:||20 Nov 2015 04:27|
|Last Modified:||20 Nov 2015 04:27|
Repository Staff Only: item control page